Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Colorcon
Harvard Business School
Moodys
McKesson

Last Updated: August 13, 2022

Investigational Drug Information for NRX-1074


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug NRX-1074?

NRX-1074 is an investigational drug.

There have been 15 clinical trials for NRX-1074. The most recent clinical trial was a Phase 2 trial, which was initiated on June 25th 2019.

The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Suicidal Ideation. The leading clinical trial sponsors are Target Health Inc., NeuroRx, Inc., and Naurex, Inc, an affiliate of Allergan plc.

There is one US patent protecting this investigational drug and forty-one international patents.

Recent Clinical Trials for NRX-1074
TitleSponsorPhase
NRX101 for Moderate Bipolar Depression and Suicidal IdeationBracket, Inc.Phase 2/Phase 3
NRX101 for Moderate Bipolar Depression and Suicidal IdeationStatistics Collaborative, Inc.Phase 2/Phase 3
NRX101 for Moderate Bipolar Depression and Suicidal IdeationTarget Health Inc.Phase 2/Phase 3

See all NRX-1074 clinical trials

Clinical Trial Summary for NRX-1074

Top disease conditions for NRX-1074
Top clinical trial sponsors for NRX-1074

See all NRX-1074 clinical trials

International Patents for NRX-1074

Drugname Country Document Number Estimated Expiration Related US Patent
NRX-1074 Australia AU2011215704 2030-02-11 See Plans and Pricing
NRX-1074 Australia AU2012328927 2030-02-11 See Plans and Pricing
NRX-1074 Australia AU2017213587 2030-02-11 See Plans and Pricing
NRX-1074 Australia AU2019204073 2030-02-11 See Plans and Pricing
NRX-1074 Brazil BR112012020142 2030-02-11 See Plans and Pricing
NRX-1074 Brazil BR112014009851 2030-02-11 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Colorcon
Harvard Business School
Moodys
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.